

This listing will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 40 (Previously presented): A method for decreasing the formation or growth of atherosclerotic lesions in a mammal comprising:

providing a soluble chimeric construct comprising P-selectin glycoprotein ligand-1 or a fragment thereof and another molecule, said chimeric construct being capable of inhibiting the interaction between P-selectin and a ligand of P-selectin; and

administering to a mammal an effective amount of said chimeric construct such that said P-selectin-ligand interaction is inhibited, wherein said chimeric construct is administered prior to, or in conjunction with, a vessel-corrective technique.

Claim 41 (Previously presented): The method of claim 40, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

Claims 42-48 (Canceled)

Claim 49 (Previously presented): The method of claim 40, wherein said chimeric construct is administered in sequential exposures over a period of hours, days, weeks, months or years.

Claim 50 (Previously presented): The method of claim 40, wherein said chimeric construct is administered in combination with other therapeutic agents.

Claim 51 (Previously presented): A method for treating or inhibiting atherosclerosis in a mammal comprising:

providing a soluble chimeric construct comprising P-selectin glycoprotein ligand-1 or a fragment thereof and another molecule, said chimeric construct being capable of inhibiting the interaction between P-selectin and a ligand of P-selectin; and

administering to a mammal an effective amount of said chimeric construct such that said P-selectin-ligand interaction is inhibited, wherein said chimeric construct is administered prior to, or in conjunction with, a vessel-corrective technique.

Claim 52 (Previously presented): The method of claim 51, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

Claim 53-58 (Canceled)

Claim 59 (Previously presented): The method of claim 51, wherein said chimeric construct is administered in sequential exposures over a period of hours, days, weeks, months or years.

Claim 60 (Previously presented): The method of claim 51, wherein said chimeric construct is administered in combination with other therapeutic agents.

Claims 61-72 (Canceled)

Claim 73 (Previously presented): A method for treating restenosis in a mammal to which a vessel-corrective technique is administered comprising:

performing a vessel-corrective technique selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery on a mammal; and

administering to said mammal, after said vessel-corrective technique, an effective amount of a soluble chimeric construct comprising P-selectin glycoprotein ligand-1 or a fragment thereof, and another molecule, said chimeric construct being capable of inhibiting the interaction

between P-selectin and a ligand of P-selectin, such that the restenosis occurring after said vessel-corrective technique is thereby treated.

Claim 74 (Canceled)